乳腺癌治疗相关的心脏功能障碍的新生物标志物的早期诊断价值
Zhengwei Wang1, Yujuan Wu1, Jingyi He1
1Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ESC heart failure
|September 17, 2025
概括
骨髓氧化酶 (MPO) 的升高与乳腺癌患者的癌症治疗相关心脏功能障碍 (CTRCD) 有关. MPO可能在心力衰竭和心肌病症中起因作用,这表明其有可能用于早期CTRCD检测.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 生物标志物 生物标志物
背景情况:
- 与癌症治疗相关的心脏功能障碍 (CTRCD) 对乳腺癌幸存者构成重大风险.
- 确定可靠的生物标志物用于早期CTRCD检测对于患者管理至关重要.
- 骨髓氧化酶 (MPO),生长差异化因子-15 (GDF-15),C反应蛋白 (CRP),胎盘生长因子 (PLGF) 和黄素-3 (Gal-3) 是潜在的生物标志物.
研究的目的:
- 通过元分析评估MPO,GDF-15,CRP,PLGF和Gal-3在乳腺癌患者中对CTRCD的诊断效用.
- 使用孟德尔随机化 (MR) 调查这些生物标志物在CTRCD中的潜在因果作用.
主要方法:
- 这是一项双相分析,结合了对12项研究 (917名患者) 的PRISMA兼容的元分析和两样本的门德尔随机化 (MR) 分析.
- 分析量化了治疗后生物标志物变化和CTRCD风险.
- 核磁共振分析利用MPO相关的单核酸多态 (SNP) 来评估心力衰竭 (HF) 和心肌病的因果关系.
主要成果:
- 分析显示,治疗后MPO,GDF-15,PLGF和CRP的显著升高.
- 升高的MPO水平与CTRCD的风险增加有关 (HR = 1.30).
- 核磁共振分析表明,MPO与HF (OR=1.06) 和心肌病 (OR=1.09) 之间存在潜在的因果关系.
结论:
- 骨髓氧化酶 (MPO) 与CTRCD中的诊断生物标志物概况和机械路径有关.
- 在乳腺癌患者中,MPO在早期CTRCD检测方面显示出作为进一步调查的潜在目标.
- 这些发现突显了MPO在CTRCD病原体中的作用及其诊断潜力.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
801
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
801
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
541
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
541
01:30Acute Coronary Syndrome III: Diagnostic Studies
218
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
218
01:30Dysrhythmias V: Evaluating Dysrhythmias
331
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
331